Using proteomics to elucidate pathogenesis and establish new diagnostic or treatment evaluation methods in refractory gastrointestinal diseases

我们鉴定了几种在肝病或炎症性肠病患者中存在的高水平血清蛋白，包括补体成分C4片段(C4-F)、激肽原片段(Kini-F)、凋亡抑制物(AIM)和人中性粒细胞多肽(HNP)-1。血清C4-F和Kini-F分别是治疗慢性丙型肝炎或诊断非酒精性脂肪性肝病(NAFLD)患者抗病毒作用的潜在生物标志物。在慢性肝病患者中，血清AIM水平与肝纤维化相关。AIM似乎也参与了NAFLD的发病机制。此外，HNP-1还恶化了NAFLD和酒精性肝病小鼠模型的病理状况，此外还有溃疡性结肠炎。因此，蛋白质组学是一种有用的工具来识别可能作为难治性胃肠道疾病候选生物标志物的蛋白质，所识别的蛋白质可能参与与这些疾病相关的病理条件。

We identified several serum proteins present at high levels in patients with liver disease or inflammatory bowel disease, including complement component C4 fragment (C4-F), kininogen fragment (Kini-F), apoptosis inhibitor (AIM), and human neutrophil peptide (HNP)-1. Serum C4-F and Kini-F are potentially biomakers for antiviral effects in patients with chronic hepatitis C or diagnosis of nonalcoholic fatty liver disease (NAFLD), respectively. In patients with chronic liver disease, serum AIM levels were associated with liver fibrosis. AIM also appeared to contribute to the pathogenesis of NAFLD. Furthermore, HNP-1 worsened pathological condition in the mouse model of NAFLD and alcoholic liver disease, in addition to ulcerative colitis. Thus, proteomics is a useful tool for identifying proteins that might serve as candidate biomarkers in refractory gastrointestinal diseases, and the identified proteins may be involve in the pathological conditions associated with those diseases.